DGAP-News: IncellDx Signs Deal With GeneCell Diagnostics to Offer New HPV Technology in India
(firmenpresse) - IncellDx
21.06.2013 14:30
---------------------------------------------------------------------------
MENLO PARK, Calif., 2013-06-21 14:30 CEST (GLOBE NEWSWIRE) --
IncellDx announced today that it has reached an agreement to offer its
proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in
India. The agreement with GeneCell Diagnostics Pvt. Ltd. of New Delhi increases
IncellDx's presence in the Indian subcontinental region, the company said.
This test is based upon IncellDx's advanced molecular diagnostic technology for
quantifying specific biomarkers that have been associated with an increased
risk of progression to cervical cancer, and will serve as a significant
resource to physicians and hospitals managing diseases associated with women's
health. CureHealth Diagnostics, GeneCell's laboratory partner, will be the
first reference laboratory in India to offer this test.
Measuring the potential oncogenic activity of the human papillomavirus (HPV) in
infected cervical cells, this novel test functions by detecting and quantifying
the expression of viral oncogenes responsible for triggering progression to
cervical cancer, resulting in a higher specificity that existing tests lack.
'IncellDx technology utilizes a flow-cytometry based method that can be used to
identify the overexpression of HPV-encoded oncogenes, offering a better
indicator of serious HPV infections than can be accomplished by identifying the
presence of HPV DNA alone,' said Dr. Dinesh Gupta, PhD., Managing Director of
GeneCell and Laboratory Director of CureHealth. 'This addition to CureHealth's
growing line of molecular diagnostic tests for women's health (cervical cancer,
breast cancer and sexually transmittable diseases) underscores our expanding
specialization in advanced clinical and diagnostic testing.'
Bruce K. Patterson MD, founder and CEO of IncellDx, commented 'The high level
of specificity our technology produces has a significant, positive economic
impact on healthcare delivery costs by potentially reducing the number of
unnecessary colposcopy/biopsies. We are excited that our partnership with
GeneCell Diagnostics will expand our global reach as well as provide better
healthcare outcomes for women in India.'
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection
and monitoring of life threatening diseases such as cervical cancer, breast
cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more
information, please visit www.incelldx.com.
About GeneCell Diagnostics Pvt. Ltd.
GeneCell Diagnostics Pvt. Ltd. is a distributor of novel molecular diagnostics
assays and technologies focused on cancer and infectious disease, based in New
Delhi.
CONTACT: Eric Hass
IncellDx, Inc.
(T) +1.650.777.7630
News Source: NASDAQ OMX
21.06.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: IncellDx
United States
Phone:
Fax:
E-mail:Internet:
ISIN: US9902652257
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 21.06.2013 - 14:30 Uhr
Sprache: Deutsch
News-ID 272045
Anzahl Zeichen: 11681
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 383 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: IncellDx Signs Deal With GeneCell Diagnostics to Offer New HPV Technology in India"
steht unter der journalistisch-redaktionellen Verantwortung von
IncellDx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
